Bosentan lowers treatment failure risk in neonates with persistent pulmonary hypertension of the newborn by 73%

This systematic review and meta-analysis examined the use of bosentan in neonates with persistent pulmonary hypertension of the newborn. The study compared bosentan-related therapy against control treatment to assess efficacy and safety outcomes.

The primary outcome was treatment failure. The meta-analysis found a lower treatment failure rate than control treatment, with a relative risk of 0.27 (95% CI: 0.14–0.51). Secondary outcomes included changes in pulmonary artery pressure, length of hospital stay, duration of mechanical ventilation, and tricuspid regurgitation values at 72 hours.

Safety data were not reported in this analysis, including information on adverse events, serious adverse events, discontinuations, or tolerability. The sample size and specific setting were also not reported. The authors did not identify specific limitations beyond the lack of reported safety and sample size details.

Clinical relevance is suggested by the significant reduction in treatment failure, though the absence of safety data limits immediate application. Further investigation into adverse event profiles is necessary before widespread adoption.